Azaña Gómez: Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Azaña Gómez, 1,799 patient HCQ late treatment study: 36% lower mortality [p<0.0001] https://c19p.org/azanagomez

copied to clipboard

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Azaña Gómez et al., Medicina Clínica, doi:10.1016/j.medcli.2022.01.008

10 Mar 2022 Source PDF Share Tweet

Retrospective 1,816 COVID-19 patients with atrial fibrillation in Spain, showing lower mortality with HCQ treatment.

Important missing comments or errors? Let us know.

risk of death, 35.8% lower, RR 0.64, p < 0.001, treatment 500 of 1,378 (36.3%), control 238 of 421 (56.5%), NNT 4.9.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

Azaña Gómez et al., 10 Mar 2022, retrospective, Spain, peer-reviewed, 10 authors, study period 1 March, 2020 - 1 October, 2020.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit